BA3182 not checked

BioAtla, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM”In the company’s words, NCT05808634 on ClinicalTrials.gov
Tested for
Advanced Adenocarcinoma
Main trialPhase 1
“The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma”In the company’s words, NCT05808634 on ClinicalTrials.gov

Other drugs for Advanced Adenocarcinoma

All 303 drugs for Advanced Adenocarcinoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 15 Sep 2028 Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BA3182

Following is part of Solo: you see every change to BA3182 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in